Harrow Health 8625 Stock Cash Per Share
| HROWL Stock | USD 25.19 0.13 0.51% |
Harrow Health 8625 fundamentals help investors to digest information that contributes to Harrow Health's financial success or failures. It also enables traders to predict the movement of Harrow Stock. The fundamental analysis module provides a way to measure Harrow Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harrow Health stock.
Harrow |
Harrow Health 8625 Company Cash Per Share Analysis
Harrow Health's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Harrow Health 8625 has a Cash Per Share of 0.0 times. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Harrow Fundamentals
| Return On Equity | 0.45 | ||||
| Number Of Shares Shorted | 4.46 K | ||||
| Revenue | 130.19 M | ||||
| EBITDA | 9.72 M | ||||
| Net Income | (24.41 M) | ||||
| Total Debt | 190.5 M | ||||
| Cash Flow From Operations | 3.84 M | ||||
| Market Capitalization | 247.48 M | ||||
| Total Asset | 312.16 M | ||||
| Retained Earnings | (133.9 M) | ||||
| Net Asset | 312.16 M |
About Harrow Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harrow Health 8625's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harrow Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harrow Health 8625 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Harrow Health Piotroski F Score and Harrow Health Altman Z Score analysis. For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Harrow Health 8625 is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.